At a glance
ClinicalIndex Comparison Record- ✓Stage 1 or Stage 2 hypertension
- ✓Left ventricular hypertrophy
- ✕Atrial fibrillation
- ✕Prior beta-blocker use for myocardial infarction or arrhythmia
- ✕Uncontrolled diabetes
- ✕Uncontrollable or symptomatic arrhythmias
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Multi-Center Study Comparing the Effects of Carvedilol Modified Release Formulation (COREG MR) and Atenolol in Combination With and Compared to an Angiotensin Converting Enzyme Inhibitor (Lisinopril) on Left Ventricular Mass Regression in Hypertensive Patients With Left Ventricular Hypertrophy (LVH).
In Brief
A Phase 3 clinical trial evaluating carvedilol MR, atenolol, and 1 other intervention for Hypertrophy, Left Ventricular. Completed, enrolled 287 participants across 78 sites.
Detailed Summary
This study is designed to compare the effects of COREG MR (carvedilol modified release formulation) to atenolol on indices of left ventricular dimensions when added to standardized angiotensin converting enzyme (ACE) inhibition, and to the effect of ACE inhibition alone. Subjects with LVH (left ventricular hypertrophy) and hypertension will be studied. The primary endpoint will be the change in left ventricular mass index (LVMI) characterized by magnetic resonance imaging (MRI) following 12 months of treatment. Secondary endpoints include the change in LV (left ventricular) mass, LV wall thickness, diastolic left ventricular filling parameters, and left ventricular ejection fraction by echocardiographic methods at Treatment Month 12. Composite outcomes and individual event data will also be evaluated by treatment group.
Study Details
Timeline
Interventions
Study drug
Comparator
Comparator